Disopain; 2-(3,4-bis(4-methoxyphenyl)isoxazol-5-yl)acetic acid; UNII-RVJ0BV3H3Y; 5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)-; Mofezolac (TN); RVJ0BV3H3Y; [3,4-Bis-(4-methoxyphenyl)isoxazol-5-yl]-acetic acid; CHEMBL259972; 2-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid; (3,4-bis(4-methoxyphenyl)-5-isoxazolyl)acetic acid; NCGC00167563-01; Mofezolac [INN]; [3,4-Bis-(4-methoxy-phenyl)isoxazol-5-yl]acetic acid; [3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid; Mofezolaco; Mofezolacum; Mofezolacum [INN-Latin]; Mofezolaco [INN-Spanish]; CCRIS 4316; [3,4-bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid; 2-[3,4-bis(4-methoxyphenyl)isoxazol-5-yl]acetic acid; BRN 5986171; 3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid; 3,4-Bis((4-methoxyphenyl)-5-isooxazolyl)acetic acid; Acetic acid, 3,4-bis(4-methoxyphenyl)-5-isooxazolyl-; Mofezolac (JAN/INN); CBKinase1_012222; CBKinase1_024622; DSSTox_CID_26716; DSSTox_RID_81848; 3,4-bis(p-Methoxyphenyl)-5-isoxazoleacetic acid; DSSTox_GSID_46716; Oprea1_261181; Oprea1_588700; MLS006011640; SCHEMBL151701; IFLab1_003830; ZINC3767; DTXSID1046716; CTK5E6276; HMS1422O02; ACN-C001061; Tox21_112558; 9783AE; BDBM50376383; STK973280; AKOS000523630; CCG-107450; MCULE-1395705248; IDI1_009937; AK129832; AS-68999; SMR000069874; BB 0262402; ST50117184; D01718; 3,4,-Di(p-methoxyphenyl)isoxazol-5-acetic Acid; 5-Isoxazoleacetic acid,3,4-bis(4-methoxyphenyl)-; [3,4-bis(4-methoxyphenyl)isoxazol-5-yl]acetic acid; BRD-K49372556-001-01-7; BRD-K49372556-001-02-5; Q15409378